Emergent BioSolutions (NYSE:EBS) Stock Price Up 7.2% – Here’s What Happened

Emergent BioSolutions Inc. (NYSE:EBS) shares shot up 7.2% during trading on Wednesday . The stock traded as high as $10.95 and last traded at $10.96. 908,581 shares changed hands during mid-day trading, a decline of 7% from the average session volume of 972,512 shares. The stock had previously closed at $10.22.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on EBS shares. Benchmark upped their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a report on Tuesday. Finally, StockNews.com upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th.

Emergent BioSolutions Stock Up 1.2 %

The stock’s 50-day simple moving average is $9.39 and its 200-day simple moving average is $9.31. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The firm has a market capitalization of $629.19 million, a P/E ratio of -2.83 and a beta of 1.60.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.88. The business had revenue of $293.80 million for the quarter, compared to analysts’ expectations of $328.72 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter in the previous year, the firm earned ($1.44) earnings per share. As a group, research analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC bought a new stake in Emergent BioSolutions during the 2nd quarter valued at $93,000. Stifel Financial Corp purchased a new position in shares of Emergent BioSolutions in the third quarter valued at $96,000. FORA Capital LLC bought a new stake in shares of Emergent BioSolutions during the 3rd quarter valued at $103,000. Landscape Capital Management L.L.C. purchased a new stake in Emergent BioSolutions during the 3rd quarter worth about $141,000. Finally, Entropy Technologies LP bought a new position in Emergent BioSolutions in the 3rd quarter worth about $155,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.